Date: 2016-12-12
Type of information: Services contract
Compound: ABX544
Company: Abivax (France) ExpreS2ion Biotechnologies (Denmark)
Therapeutic area: Infectious diseases
Type agreement: development - licensing - commercialisation
Action mechanism: polyclonal antibody. The ABX544 program targets the generation of an Ebola hyperimmune anti-serum, containing neutralising antibodies produced from animals immunised with a specific Ebola antigen. In contrast to a vaccine that needs time to generate a protective response, ABX544 should have an immediate effect when administered. It can be applied either as treatment of
infected persons or for protection of non-infected persons including health care workers, constituting a first line of defence during epidemic outbreaks.
Disease: Ebola fever
Details:
- • On December 12, 2016, ExpreS2ion Biotechnologies, a fullyowned subsidiary of ExpreS2ion Biotech Holding, and Abivax have entered into a service agreement and a term sheet for a commercial license agreement under which ExpreS2
ion and Abivax collaborate in the development of their proprietary prophylactic and treatment for Ebola virus infection, ABX544. The companies have signed a process development service agreement, as well as a term sheet for a commercial ExpreS2ion platform license agreement for ABX544, which specifies the terms and conditions for a commercial license to ExpreS2ion’s proprietary technology platform, ExpreS2. According to the service agreement, ExpreS2ion will develop a process for the GMP production of an Ebola antigen, which is required for the production of ABX544. The overall preclinical work package is expected to be executed in 2017. The corresponding license agreement is scheduled to be signed within three months.
Financial terms: The financial terms of the agreement were not disclosed.
Latest news:
Is general: Yes
